ライフサイエンスコーパス: s.c.

1 saline or AngII (600 ng . kg(-1) . min(-1), s.c.) for 2 weeks, during which they slowly developed hy

2 orally for 3 months and 4.5 x 10(6) IU IL-2 s.c. three times per week for 1 month.

3 nistered interferon (IFN)-alpha (20 MIU/m(2) s.c.) or saline for 4 weeks.

4 -33 signaling in skin, we administered IL-33 s.c. and monitored its effects at the injection site.

5 cted almost all the mice exposed to 3 LD(50) s.c. of venom.

6 y, 18 h pretreatment of rats with 6 mg/kg 6c s.c. reduces AMPH-self administration but not food self-

7 When injected into day 7 s.c. CMS4 sarcoma lesions growing in syngenic BALB/c mic

8 chondrial inhibitor rotenone (2 mg/kg/d, 7d, s.c.) induced a marked decrease in Hba-a2 and Hbb but no

9 Simultaneous injection of OTAB at a s.c. injection site remote from the sciatic nerve did no

10 LPS egress from a s.c. injection site thus occurred during many weeks and

11 cked fluorescent and radiolabeled LPS from a s.c. inoculation site to its draining lymph nodes (DLN),

12 Each construct was evaluated in a s.c. xenograft model, using CA19.9-positive (BxPC3) and

13 to male Sprague Dawley rats after starting a s.c. infusion of METH.

14 In response to a s.c. injection of KC, aged mice recruited fewer neutroph

15 Using a s.c. murine model of Lewis Lung Carcinoma, we found that

16 wer-body adipocyte hyperplasia and abdominal s.c. adipocyte hypertrophy.

17 Average abdominal s.c. adipocyte size increased by 0.16 +/- 0.06 mug lipid

18 markers of WNT activation in human abdominal s.c. adipose tissue characterized by hypertrophic obesit

19 y), consistent with the ability of abdominal s.c. adipocytes to achieve a larger size.

20 In addition, s.c. immunization with DC1s loaded with glioma-associate

21 F1-V and then boosted with either adjuvanted s.c. doses (s.c. F1-V mice) or unadjuvanted oral doses (

22 nergistically induced regression of advanced s.c. tumors, resulting in cure of some mice and developm

23 onses were generated against AML cells after s.c., but not i.v., inoculation.

24 ponse and impaired bacterial clearance after s.c. infection with S. aureus.

25 and exiting the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hep

26 analog, could achieve glycemic control after s.c. implantation in diabetic rats, with reproducible do

27 ter i.v. administration and 13-19 days after s.c. administration.

28 , and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.

29 OVA-specific T cells in lipogranulomas after s.c. immunization with NP-OVA.

30 luated in vitro or in xenografted mice after s.c. or intrahepatic injection in normal and cirrhotic (

31 (SERS) nanoparticles in a living mouse after s.c. injection.

32 nodes was observed after i.d., but not after s.c., inoculations, we used the latter model as a strate

33 and pulmonary metastasis was observed after s.c. implantation into mice, implying that activation of

34 producing IL-17 in joint tissues only after s.c. immunization.

35 f IFN-gamma KO mice, they are rejected after s.c. transplantation.

36 olecule accumulated on B cells in vivo after s.c. administration.

37 s strain induced complete protection against s.c. challenge and partial protection (70% survival) aga

38 to induce potent antitumor responses against s.c. MC38 colon adenocarcinomas in immunocompetent mice.

39 Although s.c. treatment with testosterone and aromatase inhibitor

40 Here, rats were given an s.c. injection of either saline or choline chloride dail

41 d liberation of bioactive constituents in an s.c. rat implantation model.

42 hat modular tissue engineering results in an s.c. vascularized bed that enables the transplantation o

43 These results demonstrate that an s.c. implantation approach in a 3D carrier scaffold seed

44 her inhibition of the miR-34 family using an s.c.-delivered seed-targeting 8-mer locked nucleic acid

45 ubonic plague and compare this model with an s.c. inoculations result in faster kinetics of infection

46 onse in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine, all in

47 ative-control groups were immunized i.m. and s.c. with Neisseria gonorrhoeae recombinant porin B (Ng-

48 of a range of proinflammatory mediators, and s.c. injection of cholesterol sulfate results in a Mincl

49 (+) B cells decreased B16-F10 metastasis and s.c. tumor growth, and this was IFN-gamma dependent.

50 d monocytes can acquire Ag within muscle and s.c. afferent lymph, and that HBsAg-AS01 uniquely induce

51 Strikingly, in both omental and s.c. WAT from BMI-matched obese humans, expression of Ci

52 ph nodes (MLN) and the spleen after i.p. and s.c. immunization.

53 established pulmonary metastatic tumors and s.c. tumors.

54 ce of infection of marmosets by the i.v. and s.c. exposure routes.

55 administered at two dose levels by i.v. and s.c. injection revealed that the bioavailabilty of s.c.

56 phenotypic differences between visceral and s.c. adipocytes.

57 yte hypertrophy evident in both visceral and s.c. depots.

58 Visceral and s.c. fat exhibit different intrinsic properties, includi

59 ced the anti-CNS glioma effects of DC1-based s.c. immunization.

60 evere acute thrombocytopenia in mice bearing s.c. Lewis lung carcinoma or B16F10 melanoma.

61 targeting were investigated in mice bearing s.c. Neuro2A tumors.

62 ant tumors were observed in A/J mice bearing s.c. NXS2 neuroblastomas treated with IT-IC compared wit

63 operties or the rate of germination, because s.c. inoculation with the capsulated bacillus forms also

64 aint is to use noncirculating, biodegradable s.c. implants as drug carriers that are stable throughou

65 onse to overfeeding in upper- and lower-body s.c. fat depots of 28 healthy, normal weight adults (15

66 ficant inhibition in MM tumor growth in both s.c. and i.p. models and the presence of a chemotherapeu

67 ment with polyI:C can strongly suppress both s.c. implanted TRAMP tumors in syngenic mice as well as

68 trolled levels of 17-beta-E2 administered by s.c. implant or the putative membrane estrogen receptor

69 ansformation of NRP-152 cells, as assayed by s.c. tumor growth in athymic mice, whereas silencing Sma

70 s KIM6+(pCD1Ap) led to slight attenuation by s.c. inoculation but no virulence change by i.n. inocula

71 concurrent DNA-priming strategy followed by s.c. protein boosting to again be capable of eliciting h

72 461 inhibited the growth of tumors formed by s.c. injection of mouse NIH-3T3 cells expressing oncogen

73 ansfer-based) mice were made hypertensive by s.c. infusion of angiotensin II (Ang II, 400 ng kg(-1) m

74 herapeutic vaccine were greatly increased by s.c. administration of repeated low doses in IFA.

75 ehavioral responses (scratching) produced by s.c. injection of various pruritogens in PLCbeta3- or TR

76 tant counterpart, which were implanted s.c. (s.c.) into nude mice.

77 In contrast, s.c. or i.m. immunization usually results in the formati

78 Moreover, when tested against a CT26 s.c. xenograft tumor mouse model, significant inhibition

79 A daily s.c. dose of RgIA4 prevented chemotherapy-induced neurop

80 SSc was induced in BALB/c mice by daily s.c. injections of hypochlorous acid (HOCl).

81 Starting at age 10 mo, mice received daily s.c. injections of 10 mug/mouse of MZ-5-156.

82 Herein, we demonstrate that daily s.c. injections of either Ucn 1 or Ucn 2 to 3-week-old d

83 In vivo daily s.c. administration of 10 mug MR-409 for 3 wk dramatical

84 tivector immunization eliminated small 3-day s.c. B16 tumors and strongly inhibited the growth of mor

85 ine (CLZ) (3.8 to 15 micromol/kg twice a day s.c. for 3 days) and sulpiride (SULP) (12.5 to 50 microm

86 idol (HAL) (1.3 to 4 micromol/kg twice a day s.c. for 3 days) or olanzapine (OLZ) (4 to 15 micromol/k

87 with and without Ang 1-7 (576 microg/kg/day, s.c., Alzet pumps).

88 n boosted with either adjuvanted s.c. doses (s.c. F1-V mice) or unadjuvanted oral doses (oral F1-V mi

89 However, PA was required for efficient s.c. infection by the UT500 strain, because the s.c. LD(

90 r disease induction, the rats received eight s.c. injections of Cit-ME on alternate days.

91 spectrally unique SERS nanoparticles either s.c. (R(2) = 0.998) or i.v. (R(2) = 0.992).

92 ficacy of these vaccines against established s.c. tumors.

93 d that HPK1(-/-) BMDCs eliminate established s.c. Lewis Lung Carcinoma more efficiently than their WT

94 injected intratumorally once in established s.c. AB12 (mesothelioma) and LKR (lung cancer) tumors or

95 cally reduced the growth of well-established s.c. tumors and significantly increased survival to high

96 a mRNA were higher in abdominal than femoral s.c. preadipocytes (P < 0.005 and P < 0.03, respectively

97 Following s.c. immunization of mice, which targets DC, we found su

98 Following s.c. injection of GAS, MC-deficient mice had 30% larger

99 Locomotor activity was decreased following s.c. administration of 8 and 12 mg/kg PSI but not follow

100 tudy that memory B cells generated following s.c. immunization in one footpad generate secondary resp

101 um Pi concentration occurred later following s.c. dosing (8-15 days) compared with that seen with i.v

102 enhanced transepidermal water loss following s.c. administration of IL-31.

103 ge markers, and remained organized following s.c. implantation in immunocompromised mice.

104 inally, bats that developed rabies following s.c. inoculation were significantly more likely to shed

105 produced T-dependent Ab responses following s.c. injection of 1-mum, Ag-linked microspheres, despite

106 s) in draining lymph nodes in vivo following s.c. or i.m. immunization.

107 DI5265 could be formulated at >100 mg/ml for s.c. administration and showed superior efficacy and sig

108 Furthermore, s.c. tumor rejection requires IL-17, which is produced b

109 to soluble Ag given i.p. but not to Ag given s.c. in the contralateral footpad unless LPS is coadmini

110 DC1s given s.c. migrated into draining lymph nodes, induced antigen

111 F1-V given s.c. (with adjuvant) protected 33% of the immunized mice

112 onian akinesia (0.03-0.07 mg/kg haloperidol, s.c.) or control (vehicle injection) conditions, and the

113 xPC-3 cells are responsive to exogenous HGF, s.c. tumor xenografts were grown in a paracrine manner w

114 However, s.c. immunization induces both an IFN-gamma and an IL-17

115 regressions were observed in multiple human s.c. xenograft models.

116 HLA Tg rabbits were immunized s.c. with a mixture of the three CD4-CD8 HSV-1 gD lipope

117 detection of as few as three cells implanted s.c. while maintaining long term coexpression of a repor

118 Tumors in athymic mice implanted s.c. with GH3 cells resulted in weight gain accompanied

119 Nude mice implanted s.c. with TROP-2-expressing PC3 human prostate tumor cel

120 ly as a lipid-based formulation or implanted s.c. as a cholesterol pellet.

121 cells for cytotoxicity testing or implanted s.c. into rodents to investigate scaffold immunogenicity

122 rats were either sham implanted or implanted s.c. with slow-release E2 pellets (20 ng/day for 90 days

123 (-) mutant counterpart, which were implanted s.c. (s.c.) into nude mice.

124 ules, HLA-DQ8 transgenic mice were implanted s.c. with mini-osmotic pumps capable of continuously del

125 In s.c. tumor xenografts, tumors dominated by stromal marke

126 for ERbeta over ERalpha was administered in s.c. pellets releasing 0.04 mg/d.

127 siG12D LODER on tumor growth was assessed in s.c. and orthotopic mouse models.

128 reduced the frequency of naive ART cells in s.c. fat and increased the effector-memory populations i

129 II, and grew faster than wild-type clones in s.c. and orthotopic xenograft models.

130 wild-type (WT) controls, with no decrease in s.c. tumor growth in CD47(-/-) mice.

131 ng BCL1 lymphoma but had limited efficacy in s.c. tumors.

132 , Tbx15 is 260-fold more highly expressed in s.c. preadipocytes than in epididymal preadipocytes.

133 d immunodeficiency mice, and tumor growth in s.c. and i.p. models of MM was followed.

134 cacy in reducing the rate of tumor growth in s.c. mouse tumor xenografts.

135 hox2 (Short stature homeobox 2) is higher in s.c. than visceral fat in both rodents and humans and th

136 Finally, the isotypes were studied in s.c. and i.v. tumor xenograft models, which confirmed hI

137 e, we demonstrate that IFN-gamma-independent s.c. rejection requires both CD4(+) and CD8(+) T cells.

138 ed mice fail to respond to such inflammatory s.c. challenge in contralateral footpads, unlike lymphad

139 cs could be compatible with very infrequent, s.c. dosing while maintaining a similar level of immune

140 HGF and c-Met, and MetMAb strongly inhibited s.c. tumor growth.

141 release of a peptide drug from an injectable s.c. depot.

142 However, cyclic di-GMP (cdGMP) injected s.c. shows minimal uptake into lymphatics/draining lymph

143 C iCSC clones (as few as 100 cells) injected s.c. into SCID/Beige mice formed tumors, and in one case

144 erance were evaluated in other mice injected s.c. with naloxone and tested for precipitated withdrawa

145 ) and the antagonist cyprodime were injected s.c. daily for in vivo studies or used for in vitro anal

146 C57BL/6 mice were injected s.c. with wild-type (WT), empty vector (EV), or IL-6-tra

147 When injected s.c. in mice, a single dose of microparticles sustained

148 ereas the incubation time in bats inoculated s.c. is significantly longer.

149 duced decreased tumor burden when inoculated s.c. with Lewis lung carcinoma cells.

150 The 10 mg/kg s.c. dose evoked greater increase in extracellular serot

151 PSI 8 mg/kg s.c. or p.o., but not i.p., caused neuronal loss in the

152 type mice treated with Ac-YVAD-CMK (10 mg/kg s.c. twice daily, initiated at time of CLP) did not have

153 Systemically administered zyklophin (3 mg/kg s.c.) also prevented stress-induced reinstatement of coc

154 Systemic (1-3 mg/kg s.c.) as well as central (0.3-3 nmol intracerebroventric

155 he antagonist activity of zyklophin (3 mg/kg s.c.) lasts less than 12 h, which contrasts sharply with

156 ssed the effects of AZD8529 (20 and 40 mg/kg s.c.) on male Wistar rats trained to self-administer 20%

157 f KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.) or placebo.

158 Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily.

159 object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant respo

160 ol (0.5-5 mg/kg i.p.) or raclopride (2 mg/kg s.c.).

161 g s.c., 15 min before DFP) with IMI (2 mg/kg s.c., 30 min before DFP) prevents DFP-induced convulsion

162 Coadministration of HUP (50 microg/kg s.c., 15 min before DFP) with IMI (2 mg/kg s.c., 30 min

163 retreatment with mecamylamine (6 micromol/kg s.c.), an nAChR blocker that penetrates the blood-brain

164 Nicotine (4.5-22 micromol/kg s.c., 4 injections during the 12-h light cycle for 4 day

165 ce pretreated with l-methionine (5.2 mmol/kg s.c. twice a day for 7 days) to hypermethylate promoters

166 rate that aspirin-triggered LXA4 (15 mug/kg) s.c., twice a day, reduced NF-kappaB activation and leve

167 ry were administered with morphine (10mg/kg, s.c.), midazolam (2mg/kg, i.p.), and chelerythrine chlor

168 Further, acute d-amphetamine (2mg/kg, s.c.) increased extracellular glutamate concentrations i

169 nuated both by systemic nicotine (0.5 mg/kg, s.c.) and local injection of norBNI into the amygdala.

170 by clonidine pretreatment (0.03-0.15 mg/kg, s.c.) and reduced by clonidine posttreatment (0.15 mg/kg

171 nlafaxine administration (14 days, 10 mg/kg, s.c.) elicited significant increases in cortical NE and

172 ted the effects of Tat on cocaine (10 mg/kg, s.c.) induced locomotion and conditioned place preferenc

173 ne (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain temperature homeostasis in rats maintaine

174 xamined the effects of methylone (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain temperature

175 Atipamezole (1 mg/kg, s.c.) or vehicle (sterile saline) was administered once

176 IL-1 receptor antagonist (IL-1Ra; 100 mg/kg, s.c.) or vehicle.

177 ations pretreated with capsaicin (125 mg/kg, s.c.) the facilitatory effects of 50 muM oxo-M on BAN ac

178 PSI (8, 12 or 16 mg/kg, s.c.) was administered to female Wistar rats on 6 occasi

179 ic doses of S-ketamine (5, 10, and 25 mg/kg, s.c.), and connectivity changes 15- and 30-min post-inje

180 ne D1 receptor agonist, SKF 38393 (10 mg/kg, s.c.), indicating that it reduces hyperthermia produced

181 with a fixed dose of clonidine (0.15 mg/kg, s.c.).

182 uced by clonidine posttreatment (0.15 mg/kg, s.c.).

183 mephedrone or methylone (3.0 and 10.0 mg/kg, s.c., 3 doses) caused hyperthermia but no long-term chan

184 ilar treatment with MDMA (2.5 and 7.5 mg/kg, s.c., 3 doses) evoked robust hyperthermia and persistent

185 atal days 23-28) chronic morphine (10 mg/kg, s.c., twice daily for 5 d), induced a cAMP-dependent inc

186 ol/kg, s.c.) or aminoguanidine (30 mumol/kg, s.c.) administration was evaluated.

187 fore and after 7-nitroindazole (45 mumol/kg, s.c.) or aminoguanidine (30 mumol/kg, s.c.) administrati

188 low-dose naltrexone (NTX, 0.1 ng/kg-1 pg/kg, s.c.) results in prominent opioid analgesia (lasting >4

189 In contrast, during localized s.c. infection, IL-10 production plays a detrimental rol

190 In preliminary in vivo studies using LS174T s.c. xenograft tumor bearing mouse, selective and signif

191 , soluble IL-1 Type-1 receptors (0-4 microg, s.c.) didn't appreciably affect these behaviors.

192 Moreover, s.c. inoculation of a mixture of the two cell types resu

193 ositive and EphB4-negative tumors in a mouse s.c. xenograft model.

194 ct on tumor growth was investigated in mouse s.c. tumor xenograft models.

195 or sIL-2Rbeta (0-2 microg/male Balb/c mouse; s.c.) on novelty-induced ambulatory activity and stereot

196 d over 2 days with 17beta-estradiol (10 mug, s.c.), which was repeated every 4-5 days.

197 vivo biodistribution in mice bearing Neuro2A s.c. tumors.

198 tide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension.

199 evated in response to oral and i.p., but not s.c. footpad, immunization.

200 influenced mouse survival after i.d. but not s.c. inoculation.

201 inant infected cells following i.d., but not s.c. or i.p., inoculation.

202 ved with maximal VEGF inhibition in numerous s.c. models.

203 njection revealed that the bioavailabilty of s.c. administered rh-FcgammaRIA was 27-37%.

204 e treatment protocol mediated eradication of s.c. lesions.

205 00) had little or no effect on the growth of s.c. B16 melanomas, and only Ad-Ii-TRP-2 was able to ind

206 atis was effective at delaying the growth of s.c. B16 melanomas, orthotopic 4T1 mammary carcinomas, a

207 sponses and resulted in growth inhibition of s.c. implanted CEA-expressing tumors suggesting communic

208 cancer cells in vitro and its inhibition of s.c. prostate cancer xenografts, the Hsp90 inhibitor 17-

209 Irradiation of s.c. HT-1080 tumors in nude mice administered i.v. docet

210 induced obesity, with a preferential loss of s.c. fat.

211 Using an experimental model of s.c. B. anthracis infection (an encapsulated nontoxigeni

212 In this study, we used a model of s.c. human tumor xenografts in severely immunodeficient

213 ice results in the significant regression of s.c. tumors even without being pulsed with exogenous tum

214 es for infection outcome relative to that of s.c. or i.p. inoculation, including the phenotype of inf

215 transferred TDLN B cells in the treatment of s.c. tumors as well as metastatic pulmonary tumors.

216 U-Omp19 s.c. delivery induces the recruitment of CD11c(+)CD8alph

217 ifferent weights implanted in the abdomen or s.c. on the back, reversibly decreases the biological bo

218 und that C57BL/6 mice given intratracheal or s.c. immunization of conidia prior to corneal infection

219 In mice bearing orthotopic or s.c. prostate cancer tumors, we show that FTY720 dramati

220 implanted orthotopically in the prostate or s.c. in the flank.

221 or cells encapsulated in alginate slabs) or s.c. enclosed in oxygenating and immunoisolating betaAir

222 genicity of KRN23 following a single i.v. or s.c. dose of KRN23 in adults with XLH.

223 After i.v. or s.c. priming, partial proliferation and activation of CD

224 w-derived dendritic cells via i.p., i.v., or s.c. routes.

225 ntly PSI (8 mg/kg) was administered by oral, s.c. and i.p. routes on alternate days to separate group

226 , and intraperitoneal and subcutaneous (i.p./s.c.) routes.

227 Currently, 3 of 4 i.p./s.c.- and 2 of 4 p.o. secondary passage-inoculated cats

228 animals were vaccinated with 1.0 x 10(4) PFU s.c. at day 42 of gestation, when fetal sensitivity to R

229 Priming s.c. with 60 mug of both HIV Gag p24 vaccines elicited p

230 Study subjects also received s.c. injections of GM-CSF at a fixed dose.

231 ase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2

232 nd persisted longer in patients who received s.c. administration.

233 from RR MS patients treated with recombinant s.c. injected IFN-beta-1b revealed that they induced a s

234 Remarkably, s.c. tumor volume and lung metastasis were increased 2-f

235 Prime-boost vaccination via sequential s.c. and i.m. administration yielded greater efficacy th

236 In the in vivo setting, s.c. xenografts of WiT49 cells resembled malignant rhabd

237 d with topical applications or with a single s.c. injection of Ac2-26 revealed the anti-inflammatory

238 blished arthritis were treated with a single s.c. injection of rh-FcgammaRIA (0.2-2.0 mg/dose) given

239 expressed between visceral and subcutaneous (s.c.) fat in both humans and rodents, and in humans visc

240 y the intramuscular (i.m.) and subcutaneous (s.c.) routes with recombinant MOMP (rMOMP) from Chlamydi

241 rimed with adjuvant-containing subcutaneous (s.c.) doses of F1-V and then boosted with either adjuvan

242 g i.d. inoculation of the ear, subcutaneous (s.c.) inoculation of the footpad, or inoculation of the

243 ble latent infection following subcutaneous (s.c.) immunization.

244 examined the role of toxins in subcutaneous (s.c.) infections using two different genetically complet

245 After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients rece

246 g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak CD8(+) T-cell response

247 were highly attenuated by the subcutaneous (s.c.) route.

248 Despite this, subcutaneous (s.c.) models of infection are broadly used in many field

249 e show here that survival upon subcutaneous (s.c.) VSV challenge was independent of neutralizing anti

250 (Callithrix jacchus) by i.v., subcutaneous (s.c.), and intranasal exposure routes to more closely mi

251 y saline or morphine (10mg/kg, subcutaneous, s.c.), followed 30min later by either saline or midazola

252 the strain was administered subcutaneously (s.c.).

253 1.0 x 10(5) PFU administered subcutaneously (s.c.).

254 homologous protein delivered subcutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t

255 ium glutamate (MSG) (4 mg/g) subcutaneously (s.c.) at 2nd,4th, 6th, 8th,10th postnatal day.

256 er intramuscularly (i.m.) or subcutaneously (s.c.) with a homologous or heterologous RABV.

257 tered intranasally (i.n.) or subcutaneously (s.c.), developed similar levels of malaria-specific IgG1

258 T cell activation in response to subsequent s.c. AML cell challenge.

259 Systemic (s.c.) injection in naive mice of cyclic AMP-phosphodiest

260 e serum immunoglobulin G1 (IgG1) titers than s.c. F1-V mice.

261 model for cystic fibrosis (CF), we show that s.c. injection or oral administration of PTC124 to Cftr-

262 disease, we have defined in this study that s.c. or intranasal sensitization followed by airway chal

263 The s.c. administration of the MOR agonist, [D-Arg2, Lys4] d

264 The s.c. implantable device allows for controlled and adequa

265 The s.c. infusion of 20-HETE shortened the tail bleeding tim

266 ivity to 1F5mIgG2a, particularly against the s.c. tumors.

267 Although the s.c. site satisfies both these criteria, the site is poo

268 neys of immunodeficient mice, as well as the s.c. implantation for preclinical drug testing, includin

269 . infection by the UT500 strain, because the s.c. LD(50) of a UT500 PA(-) mutant was 10,000-fold high

270 of the dual-label (111)In-RDC018 in both the s.c. and metastatic growing tumor model.

271 In contrast, the s.c. environment is replete with IL-6 and supports the i

272 ubonic plague differs significantly from the s.c. model in multiple aspects of infection.

273 WISP2 activation in the s.c. adipose tissue, but not in visceral fat, identified

274 sly shown to be moderately attenuated in the s.c. model, was severely attenuated in the i.d.

275 0064 has wide bioavailability, including the s.c. and oral routes.

276 antly, immunization via the i.n. but not the s.c. route elicited sporozoite neutralizing antibodies c

277 ics of PC-3 cells in vitro and prevented the s.c. growth of PC-3 cells in severe combined immunodefic

278 e peripheral circulation, and migrate to the s.c. immunization sites.

279 Using the s.c. B16F10 melanoma model, we found that a nontoxic dos

280 anted OVA and OVA+CAF09 administered via the s.c. or i.m. routes.

281 In summary, bats inoculated via the s.c. route are more likely to shed virus, thus increasin

282 rowth of these cells in vivo following their s.c. injection into syngeneic immunocompetent (but not i

283 g second-trimester human fetal heart tissues s.c. into the ear pinna of a SCID mouse.

284 nistration of DT-A nanoparticles directly to s.c. xenograft tumors and to the peritoneal cavity of mi

285 prolonged tumor mice survival as a tolerated s.c. agent.

286 cy confers protection against transplantable s.c. melanoma outgrowth and melanoma lung metastatic col

287 These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vit

288 Using s.c. injections of vascular endothelial growth factor or

289 e these results open the potential for using s.c. islet delivery as a treatment option for type I dia

290 Mice vaccinated s.c. with 3.8 x 10(7) CFU of the Deltacrp mutant develop

291 e microbeads resulted in highly vascularized s.c. tissue containing up to 16-fold more capillaries in

292 bone erosion) is similar in the i.p. versus s.c. immunized mice despite the presence of CD4(+) T cel

293 eceptor agonist administered twice daily via s.c. injection, improves glycemic control, often with as

294 M. ulcerans was s.c. inoculated in three consanguine mouse strains, that

295 (n = 10) or sinusitis (controls, n = 6) were s.c. co-implanted with healthy allogeneic human nasal ca

296 se tissue and bone marrow aspirates and were s.c. implanted into immunodeficient mice in the presence

297 nization route with respect to efficacy were s.c. >/= mucosal > i.m.

298 When s.c. inoculated, both EMT and non-EMT cells established

299 rameters to near background by 8 wk, whereas s.c. DC10 treatments did not affect AHR but did reduce t

300 had been diabetic for 2 mo were treated with s.c. injections of saline (control) or murine leptin (0.